Artia Global Partners LP acquired a new stake in Celcuity, Inc. (NASDAQ:CELC - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 59,316 shares of the company's stock, valued at approximately $6,206,000. Celcuity makes up about 1.1% of Artia Global Partners LP's portfolio, making the stock its 17th largest position. Artia Global Partners LP owned 0.12% of Celcuity as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds also recently made changes to their positions in CELC. NEA Management Company LLC grew its stake in Celcuity by 64.9% during the 4th quarter. NEA Management Company LLC now owns 3,535,561 shares of the company's stock worth $352,637,000 after buying an additional 1,391,300 shares during the last quarter. Avoro Capital Advisors LLC purchased a new stake in Celcuity in the fourth quarter valued at approximately $310,302,000. Soleus Capital Management L.P. boosted its holdings in shares of Celcuity by 17.0% in the second quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company's stock valued at $40,208,000 after acquiring an additional 437,696 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Celcuity by 10.7% in the fourth quarter. Vanguard Group Inc. now owns 2,279,433 shares of the company's stock valued at $227,351,000 after acquiring an additional 220,386 shares during the period. Finally, State Street Corp grew its position in shares of Celcuity by 126.6% during the fourth quarter. State Street Corp now owns 1,637,687 shares of the company's stock worth $163,343,000 after acquiring an additional 914,887 shares during the last quarter. Hedge funds and other institutional investors own 63.33% of the company's stock.
Celcuity Stock Up 3.0%
CELC opened at $95.08 on Thursday. The company has a debt-to-equity ratio of 6.04, a current ratio of 8.93 and a quick ratio of 8.93. Celcuity, Inc. has a 12 month low of $44.42 and a 12 month high of $151.02. The stock has a market capitalization of $4.65 billion, a P/E ratio of -22.11 and a beta of 0.20. The business has a 50 day simple moving average of $94.52 and a 200-day simple moving average of $107.38.
Celcuity (NASDAQ:CELC - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.28). On average, equities analysts anticipate that Celcuity, Inc. will post -4.75 earnings per share for the current fiscal year.
Analyst Ratings Changes
CELC has been the topic of a number of recent research reports. Stifel Nicolaus cut their target price on shares of Celcuity from $175.00 to $150.00 and set a "buy" rating on the stock in a report on Friday, August 14th. Leerink Partners set a $155.00 price target on shares of Celcuity in a research note on Tuesday, June 2nd. Citizens Jmp reissued a "market outperform" rating and set a $177.00 price objective on shares of Celcuity in a research report on Monday, August 17th. Macquarie Infrastructure set a $160.00 price objective on shares of Celcuity in a research note on Thursday, May 28th. Finally, Wells Fargo & Company dropped their price objective on shares of Celcuity from $183.00 to $166.00 and set an "overweight" rating on the stock in a research note on Wednesday, June 3rd. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $154.55.
Read Our Latest Stock Analysis on CELC
About Celcuity
(
Free Report)
Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.
Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Celcuity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.
While Celcuity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
